{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:49:59Z","timestamp":1792792199601,"version":"4.5.0"},"reference-count":140,"publisher":"Elsevier","isbn-type":[{"value":"9780128140871","type":"print"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/bs.apha.2017.09.009","type":"book-chapter","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T03:35:11Z","timestamp":1515728111000},"page":"137-162","source":"Crossref","is-referenced-by-count":172,"title":["Unique Effects of Clozapine: A Pharmacological Perspective"],"prefix":"10.1016","author":[{"given":"Jibran Y.","family":"Khokhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Henricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily D.K.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan I.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0010","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/10550490701389658","article-title":"Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia","volume":"16","author":"Akerele","year":"2007","journal-title":"The American Journal on Addictions"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40429-014-0034-7","article-title":"Pharmacotherapy of co-occurring schizophrenia and substance use disorders","volume":"1","author":"Akerman","year":"2014","journal-title":"Current Addiction Reports"},{"issue":"5","key":"10.1016\/bs.apha.2017.09.009_bb0020","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1176\/ajp.151.5.780b","article-title":"Decreased substance use in chronically psychotic patients treated with clozapine","volume":"151","author":"Albanese","year":"1994","journal-title":"The American Journal of Psychiatry"},{"issue":"2\u20133","key":"10.1016\/bs.apha.2017.09.009_bb0025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0165-0173(99)00027-2","article-title":"Schizophrenia: The fundamental questions","volume":"31","author":"Andreasen","year":"2000","journal-title":"Brain Research. Brain Research Reviews"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/(SICI)1098-2396(199612)24:4<349::AID-SYN5>3.0.CO;2-D","article-title":"Pharmacological actions of the atypical antipsychotic drug clozapine: A review","volume":"24","author":"Ashby","year":"1996","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/(SICI)1098-2396(19991215)34:4<245::AID-SYN1>3.0.CO;2-D","article-title":"Medial prefrontal cortical output neurons to the ventral tegmental area (VTA) and their responses to burst-patterned stimulation of the VTA: Neuroanatomical and in vivo electrophysiological analyses","volume":"34","author":"Au-Young","year":"1999","journal-title":"Synapse"},{"key":"10.1016\/bs.apha.2017.09.009_bb0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1192\/S0007125000296852","article-title":"Do central antiadrenergic actions contribute to the atypical properties of clozapine?","volume":"17","author":"Baldessarini","year":"1992","journal-title":"The British Journal of Psychiatry. Supplement"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2017.09.009_bb0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2008.06.020","article-title":"Negative symptoms are associated with less alcohol use, craving, and \u201chigh\u201d in alcohol dependent patients with schizophrenia","volume":"105","author":"Batki","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/schbul\/sbs077","article-title":"Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: Implications for substance abuse in schizophrenia","volume":"39","author":"Bedard","year":"2013","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.jcp.0000169419.38899.5b","article-title":"Aripiprazole in schizophrenia with cocaine dependence: A pilot study","volume":"25","author":"Beresford","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/npp.1994.1","article-title":"The effect of clozapine on plasma norepinephrine: Relationship to clinical efficacy","volume":"10","author":"Breier","year":"1994","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/bs.apha.2017.09.009_bb0065","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.v66n0613","article-title":"Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole","volume":"66","author":"Brown","year":"2005","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/bs.apha.2017.09.009_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.alcohol.2016.02.006","article-title":"An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder","volume":"53","author":"Brunette","year":"2016","journal-title":"Alcohol"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/17523280903156073","article-title":"An open label study of quetiapine in patients with schizophrenia and alcohol disorders","volume":"2","author":"Brunette","year":"2009","journal-title":"Mental Health and Substance Use"},{"issue":"1\u20132","key":"10.1016\/bs.apha.2017.09.009_bb0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15504263.2011.570118","article-title":"A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia","volume":"7","author":"Brunette","year":"2011","journal-title":"Journal of Dual Diagnosis"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0085","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/sbl003","article-title":"Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders","volume":"32","author":"Brunette","year":"2006","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/bs.apha.2017.09.009_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2017.06.039","article-title":"Demographic and clinical correlates of substance use disorders in first episode psychosis","author":"Brunette","year":"2017","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1176\/ajp.154.3.363","article-title":"Attentional impairments in deficit and nondeficit forms of schizophrenia","volume":"154","author":"Buchanan","year":"1997","journal-title":"The American Journal of Psychiatry"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1176\/ajp.151.3.385","article-title":"Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy","volume":"151","author":"Buckley","year":"1994","journal-title":"The American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/CLT-100102873","article-title":"The pharmacology and toxicology of atypical antipsychotic agents","volume":"39","author":"Burns","year":"2001","journal-title":"Journal of Toxicology. Clinical Toxicology"},{"key":"10.1016\/bs.apha.2017.09.009_bb0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1192\/bjp.174.2.150","article-title":"Prevalence of substance misuse in first-episode psychosis","volume":"174","author":"Cantwell","year":"1999","journal-title":"The British Journal of Psychiatry"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"The American Journal of Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1300\/J374v03n02_04","article-title":"Animal modeling and neurocircuitry of dual diagnosis","volume":"3","author":"Chambers","year":"2007","journal-title":"Journal of Dual Diagnosis"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0006-3223(01)01134-9","article-title":"A neurobiological basis for substance abuse comorbidity in schizophrenia","volume":"50","author":"Chambers","year":"2001","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1016\/bs.apha.2017.09.009_bb0130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/gbb.12051","article-title":"Cortical-striatal gene expression in neonatal hippocampal lesion (NVHL)-amplified cocaine sensitization","volume":"12","author":"Chambers","year":"2013","journal-title":"Genes, Brain, and Behavior"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0135","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.neuropharm.2011.05.007","article-title":"Raclopride lessens the ability of clozapine to suppress alcohol drinking in Syrian golden hamsters","volume":"61","author":"Chau","year":"2011","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.neuropharm.2009.10.006","article-title":"Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters","volume":"58","author":"Chau","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.apha.2017.09.009_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpsychires.2015.07.010","article-title":"Desipramine enhances the ability of paliperidone to decrease alcohol drinking","volume":"69","author":"Chau","year":"2015","journal-title":"Journal of Psychiatric Research"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-005-2174-x","article-title":"Predictors and markers of clozapine response","volume":"179","author":"Chung","year":"2005","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/bs.apha.2017.09.009_bb0160","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0006-3223(01)01271-9","article-title":"Management of treatment resistance in schizophrenia","volume":"50","author":"Conley","year":"2001","journal-title":"Biological Psychiatry"},{"issue":"4238","key":"10.1016\/bs.apha.2017.09.009_bb0165","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00393581","article-title":"Clozapine-induced agranulocytosis. A genetic and epidemiologic study","volume":"37","author":"de la Chapelle","year":"1977","journal-title":"Human Genetics"},{"issue":"Suppl. 1","key":"10.1016\/bs.apha.2017.09.009_bb0175","first-page":"5","article-title":"Role of norepinephrine in depression","volume":"61","author":"Delgado","year":"2000","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1016\/bs.apha.2017.09.009_bb0180","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"The American Journal of Psychiatry"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0022-3956(94)90010-8","article-title":"Patterns of substance abuse in schizophrenia: Nature and significance","volume":"28","author":"DeQuardo","year":"1994","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00213-002-1381-y","article-title":"Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic","volume":"167","author":"Devoto","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.apha.2017.09.009_bb0195","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2105\/AJPH.86.7.973","article-title":"Persons with dual diagnoses of substance abuse and major mental illness: Their excess costs of psychiatric care","volume":"86","author":"Dickey","year":"1996","journal-title":"American Journal of Public Health"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0200","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/oxfordjournals.schbul.a033464","article-title":"The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia","volume":"26","author":"Drake","year":"2000","journal-title":"Schizophrenia Bulletin"},{"issue":"13","key":"10.1016\/bs.apha.2017.09.009_bb0205","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1517\/14656566.2012.709235","article-title":"Clozapine for the treatment of schizophrenia","volume":"13","author":"Fakra","year":"2012","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/bs.apha.2017.09.009_bb0210","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1749-6632.1988.tb42107.x","article-title":"Mesocorticolimbic dopamine systems and reward","volume":"537","author":"Fibiger","year":"1988","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2017.09.009_bb0215","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.schres.2014.04.033","article-title":"Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC","volume":"158","author":"Fischer","year":"2014","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0220","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157488608784529251","article-title":"Side effects of clozapine and some other psychoactive drugs","volume":"3","author":"Flanagan","year":"2008","journal-title":"Current Drug Safety"},{"issue":"1\u20132","key":"10.1016\/bs.apha.2017.09.009_bb0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.psychres.2008.07.026","article-title":"Relative food preference and hedonic judgments in schizophrenia","volume":"175","author":"Folley","year":"2010","journal-title":"Psychiatry Research"},{"key":"10.1016\/bs.apha.2017.09.009_bb0230","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.ps.43.020192.001511","article-title":"Schizophrenia: Diathesis-stress revisited","volume":"43","author":"Fowles","year":"1992","journal-title":"Annual Review of Psychology"},{"key":"10.1016\/bs.apha.2017.09.009_bb0235","series-title":"Substance abuse: A comprehensive texbook","first-page":"61","article-title":"Brain reward mechanisms","author":"Gardner","year":"1997"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(91)90196-U","article-title":"Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia","volume":"41","author":"Grace","year":"1991","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0245","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0165-1781(93)90016-A","article-title":"Clozapine response and plasma catecholamines and their metabolites","volume":"46","author":"Green","year":"1993","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0250","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0920-9964(02)00231-1","article-title":"Alcohol and cannabis use in schizophrenia: Effects of clozapine vs. risperidone","volume":"60","author":"Green","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psychres.2004.05.005","article-title":"Clozapine reduces alcohol drinking in Syrian golden hamsters","volume":"128","author":"Green","year":"2004","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0260","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/schbul\/sbv136","article-title":"Different paths to core pathology: The equifinal model of the schizophrenia syndrome","volume":"42","author":"Green","year":"2016","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jsat.2007.01.008","article-title":"Substance abuse and schizophrenia: Pharmacotherapeutic intervention","volume":"34","author":"Green","year":"2008","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/bs.apha.2017.09.009_bb0270","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10673229909017206","article-title":"Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?","volume":"6","author":"Green","year":"1999","journal-title":"Harvard Review of Psychiatry"},{"key":"10.1016\/bs.apha.2017.09.009_bb0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0014-2999(89)90765-6","article-title":"Clonidine modulates dopamine cell firing in rat ventral tegmental area","volume":"165","author":"Grenhoff","year":"1989","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0280","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.psychres.2014.04.038","article-title":"Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster","volume":"218","author":"Gulick","year":"2014","journal-title":"Psychiatry Research"},{"issue":"11","key":"10.1016\/bs.apha.2017.09.009_bb0285","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0006-3223(95)00609-5","article-title":"Substance abuse and the onset of schizophrenia","volume":"40","author":"Hambrecht","year":"1996","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0290","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamapsychiatry.2013.3726","article-title":"Comorbidity of severe psychotic disorders with measures of substance use","volume":"71","author":"Hartz","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/bs.apha.2017.09.009_bb0295","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1192\/bjp.bp.109.072249","article-title":"Psychosis reactivity to cannabis use in daily life: An experience sampling study","volume":"196","author":"Henquet","year":"2010","journal-title":"The British Journal of Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0300","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1447-0349.2007.00506.x","article-title":"Side-effects and treatment with clozapine: A comparison between the views of consumers and their clinicians","volume":"17","author":"Hodge","year":"2008","journal-title":"International Journal of Mental Health Nursing"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0305","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00131746-200605000-00002","article-title":"Suicide in schizophrenia: Findings from a national clinical survey","volume":"12","author":"Hunt","year":"2006","journal-title":"Journal of Psychiatric Practice"},{"key":"10.1016\/bs.apha.2017.09.009_bb0310","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.neuro.29.051605.113009","article-title":"Neural mechanisms of addiction: The role of reward-related learning and memory","volume":"29","author":"Hyman","year":"2006","journal-title":"Annual Review of Neuroscience"},{"issue":"7935","key":"10.1016\/bs.apha.2017.09.009_bb0315","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(75)90206-8","article-title":"Letter: Clozapine and agranulocytosis","volume":"2","author":"Idanpaan-Heikkila","year":"1975","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0320","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","article-title":"Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties","volume":"244","author":"Janssen","year":"1988","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"10","key":"10.1016\/bs.apha.2017.09.009_bb0325","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0330","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuroimage.2005.07.051","article-title":"Dysfunction of ventral striatal reward prediction in schizophrenia","volume":"29","author":"Juckel","year":"2006","journal-title":"NeuroImage"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2017.09.009_bb0335","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(03)01308-6","article-title":"alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs","volume":"462","author":"Kalkman","year":"2003","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0340","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/10550490590924728","article-title":"Co-morbidity of smoking in patients with psychiatric and substance use disorders","volume":"14","author":"Kalman","year":"2005","journal-title":"The American Journal on Addictions"},{"issue":"6","key":"10.1016\/bs.apha.2017.09.009_bb0345","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1034\/j.1600-0447.2000.101006452.x","article-title":"The prevalence of comorbid substance misuse and its influence on suicidal ideation among in-patients with schizophrenia","volume":"101","author":"Kamali","year":"2000","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0350","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamapsychiatry.2015.2966","article-title":"The role of clozapine in treatment-resistant schizophrenia","volume":"73","author":"Kane","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1016\/bs.apha.2017.09.009_bb0355","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb9000","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: A systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"International Clinical Psychopharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2017.09.009_bb0360","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/10673229709030550","article-title":"The self-medication hypothesis of substance use disorders: A reconsideration and recent applications","volume":"4","author":"Khantzian","year":"1997","journal-title":"Harvard Review of Psychiatry"},{"key":"10.1016\/bs.apha.2017.09.009_bb0365","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.drugalcdep.2015.04.003","article-title":"Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan","volume":"152","author":"Khokhar","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.apha.2017.09.009_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2017.04.016","article-title":"The link between schizophrenia and substance use disorder: A unifying hypothesis","author":"Khokhar","year":"2017","journal-title":"Schizophrenia Research"},{"key":"10.1016\/bs.apha.2017.09.009_bb0375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neuropharm.2016.01.017","article-title":"Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster","volume":"105","author":"Khokhar","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.apha.2017.09.009_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2017.02.029","article-title":"Behavioral predictors of alcohol drinking in a neurodevelopmental rat model of schizophrenia and co-occurring alcohol use disorder","author":"Khokhar","year":"2017","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1016\/bs.apha.2017.09.009_bb0385","first-page":"609","article-title":"Treatment cost and rehospitalization rate in schizophrenic outpatients with a history of substance abuse","volume":"42","author":"Kivlahan","year":"1991","journal-title":"Hospital & Community Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0390","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1600-0447.1984.tb02482.x","article-title":"Cannabis and neuroleptic agents in schizophrenia","volume":"69","author":"Knudsen","year":"1984","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0395","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/schbul\/23.2.195","article-title":"Substance use disorder and the early course of illness in schizophrenia and affective psychosis","volume":"23","author":"Kovasznay","year":"1997","journal-title":"Schizophrenia Bulletin"},{"issue":"20","key":"10.1016\/bs.apha.2017.09.009_bb0400","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1001\/jama.284.20.2606","article-title":"Smoking and mental illness: A population-based prevalence study","volume":"284","author":"Lasser","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/bs.apha.2017.09.009_bb0405","series-title":"Schizophrenia research","first-page":"341","article-title":"Biochemical effects of clozapine in cerebrospinal fluid of patients of schizophrenia","author":"Leiberman","year":"1991"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0410","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophrenia Bulletin"},{"issue":"12","key":"10.1016\/bs.apha.2017.09.009_bb0415","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0420","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archpsyc.1994.03950040017002","article-title":"Cannabis abuse and the course of recent-onset schizophrenic disorders","volume":"51","author":"Linszen","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0425","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00005053-199402000-00008","article-title":"Relationship of positive and negative symptoms to cocaine abuse in schizophrenia","volume":"182","author":"Lysaker","year":"1994","journal-title":"The Journal of Nervous and Mental Disease"},{"issue":"7","key":"10.1016\/bs.apha.2017.09.009_bb0430","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0269881114527357","article-title":"The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study","volume":"28","author":"Machielsen","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.apha.2017.09.009_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2017.03.030","article-title":"Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study","author":"Machielsen","year":"2017","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1016\/bs.apha.2017.09.009_bb0440","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.161.5.818","article-title":"A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone","volume":"161","author":"Mamo","year":"2004","journal-title":"The American Journal of Psychiatry"},{"issue":"6","key":"10.1016\/bs.apha.2017.09.009_bb0445","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1176\/ajp.152.6.959a","article-title":"Reduction of comorbid substance abuse with clozapine","volume":"152","author":"Marcus","year":"1995","journal-title":"The American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia\u2014The role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Current Medical Research and Opinion"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0455","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"10.1016\/bs.apha.2017.09.009_bb0460","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4088\/JCP.v64n0920","article-title":"Reducing the risk for suicide in schizophrenia and affective disorders","volume":"64","author":"Meltzer","year":"2003","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0465","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2017.09.009_bb0470","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2014.03.002","article-title":"Schizophrenia and co-occurring substance use disorder: Reward, olfaction and clozapine","volume":"155","author":"Mesholam-Gately","year":"2014","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0475","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4088\/JCP.v66n0418","article-title":"Clozapine diminishes suicidal behavior: A retrospective evaluation of clinical records","volume":"66","author":"Modestin","year":"2005","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/bs.apha.2017.09.009_bb0480","series-title":"American psychiatric press review of psychiatry","first-page":"351","article-title":"Cellular interactions in the prefrontal cortex: a major focus of schizophrenia research","author":"Moghaddam","year":"1996"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0485","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-004-1981-9","article-title":"Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement","volume":"178","author":"Molina","year":"2005","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0490","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.pnpbp.2007.12.028","article-title":"Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients","volume":"32","author":"Molina","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"6","key":"10.1016\/bs.apha.2017.09.009_bb0495","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/schbul\/sbs149","article-title":"Brain circuits that link schizophrenia to high risk of cigarette smoking","volume":"39","author":"Moran","year":"2013","journal-title":"Schizophrenia Bulletin"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2017.09.009_bb0500","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.schres.2012.08.033","article-title":"Insular and anterior cingulate circuits in smokers with schizophrenia","volume":"142","author":"Moran","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0505","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/schbul\/16.1.31","article-title":"Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates","volume":"16","author":"Mueser","year":"1990","journal-title":"Schizophrenia Bulletin"},{"issue":"8","key":"10.1016\/bs.apha.2017.09.009_bb0510","first-page":"649","article-title":"The CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians","volume":"23","author":"Naber","year":"2009","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0515","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/03007990152673864","article-title":"Focus on clozapine","volume":"17","author":"Naheed","year":"2001","journal-title":"Current Medical Research and Opinion"},{"issue":"2\u20133","key":"10.1016\/bs.apha.2017.09.009_bb0520","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.schres.2014.12.024","article-title":"Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data","volume":"161","author":"Nakajima","year":"2015","journal-title":"Schizophrenia Research"},{"key":"10.1016\/bs.apha.2017.09.009_bb0525","first-page":"321","article-title":"The effects of cannabis use on the clinical condition of schizophrenics","volume":"67","author":"Negrete","year":"1986","journal-title":"NIDA Research Monograph"},{"issue":"12","key":"10.1016\/bs.apha.2017.09.009_bb0530","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2012.847","article-title":"Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia","volume":"69","author":"Nielsen","year":"2012","journal-title":"Archives of General Psychiatry"},{"issue":"10","key":"10.1016\/bs.apha.2017.09.009_bb0535","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.02.007","article-title":"Alterations of the brain reward system in antipsychotic naive schizophrenia patients","volume":"71","author":"Nielsen","year":"2012","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0540","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0773.1995.tb00123.x","article-title":"Nicotine dependence, midbrain dopamine systems and psychiatric disorders","volume":"76","author":"Nisell","year":"1995","journal-title":"Pharmacology & Toxicology"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0545","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ps.201500324","article-title":"Clozapine for schizophrenia: State variation in evidence-based practice","volume":"67","author":"Olfson","year":"2016","journal-title":"Psychiatric Services"},{"issue":"6","key":"10.1016\/bs.apha.2017.09.009_bb0550","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"Journal of Psychiatric Research"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0555","first-page":"253","article-title":"The risk of suicide after clozapine discontinuation: Cause for concern","volume":"27","author":"Patchan","year":"2015","journal-title":"Annals of Clinical Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0560","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0447.1992.tb01456.x","article-title":"Influence of cannabis abuse on schizophrenic psychopathology","volume":"85","author":"Peralta","year":"1992","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/bs.apha.2017.09.009_bb0565","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neubiorev.2016.12.013","article-title":"The neural diathesis-stress model of schizophrenia revisited: An update on recent findings considering illness stage and neurobiological and methodological complexities","volume":"73","author":"Pruessner","year":"2017","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"5768","key":"10.1016\/bs.apha.2017.09.009_bb0570","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/286074a0","article-title":"Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats","volume":"286","author":"Pycock","year":"1980","journal-title":"Nature"},{"issue":"19","key":"10.1016\/bs.apha.2017.09.009_bb0575","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/bs.apha.2017.09.009_bb0580","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM199709183371202","article-title":"A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia","volume":"337","author":"Rosenheck","year":"1997","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apha.2017.09.009_bb9005","series-title":"Genetic theory and abnormal behavior","author":"Rosenthal","year":"1970"},{"issue":"6","key":"10.1016\/bs.apha.2017.09.009_bb0585","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.nmd.0000165089.14736.bf","article-title":"Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol","volume":"193","author":"Sayers","year":"2005","journal-title":"The Journal of Nervous and Mental Disease"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0590","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1345\/aph.1G396","article-title":"Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring","volume":"40","author":"Schulte","year":"2006","journal-title":"The Annals of Pharmacotherapy"},{"issue":"12","key":"10.1016\/bs.apha.2017.09.009_bb0595","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0006-3223(98)00199-1","article-title":"Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia","volume":"45","author":"See","year":"1999","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0600","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/schbul\/16.1.111","article-title":"Pharmacological treatment of substance-abusing schizophrenic patients","volume":"16","author":"Siris","year":"1990","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0605","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/j.1552-4604.1997.tb04773.x","article-title":"Effect of patient and family insight on compliance of schizophrenic patients","volume":"37","author":"Smith","year":"1997","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2017.09.009_bb0610","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1176\/ajp.133.2.197","article-title":"The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor","volume":"133","author":"Snyder","year":"1976","journal-title":"The American Journal of Psychiatry"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0615","first-page":"245","article-title":"Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine","volume":"21","author":"Spivak","year":"1998","journal-title":"Clinical Neuropharmacology"},{"issue":"10","key":"10.1016\/bs.apha.2017.09.009_bb0620","first-page":"603","article-title":"The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine (clozapine)","volume":"26","author":"Stille","year":"1971","journal-title":"Il Farmaco; edizione pratica"},{"issue":"23","key":"10.1016\/bs.apha.2017.09.009_bb0625","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","article-title":"N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity","volume":"100","author":"Sur","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/bs.apha.2017.09.009_bb0630","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","article-title":"Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality","volume":"27","author":"Svensson","year":"2003","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0635","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archgenpsychiatry.2011.1503","article-title":"Use and abuse of alcohol and illicit drugs in US adolescents: Results of the national comorbidity survey-adolescent supplement","volume":"69","author":"Swendsen","year":"2012","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1016\/bs.apha.2017.09.009_bb0640","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/mp.2012.109","article-title":"Striatal dopamine release in schizophrenia comorbid with substance dependence","volume":"18","author":"Thompson","year":"2013","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/bs.apha.2017.09.009_bb0645","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1192\/bjp.bp.116.194019","article-title":"Influence of childhood trauma on diagnosis and substance use in first-episode psychosis","volume":"211","author":"Tomassi","year":"2017","journal-title":"The British Journal of Psychiatry"},{"issue":"10","key":"10.1016\/bs.apha.2017.09.009_bb0650","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1176\/ajp.135.10.1213","article-title":"Marijuana use in schizophrenia: A clear hazard","volume":"135","author":"Treffert","year":"1978","journal-title":"The American Journal of Psychiatry"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2017.09.009_bb0655","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2012.01.016","article-title":"Effect of cannabis use on the course of schizophrenia in male patients: A prospective cohort study","volume":"137","author":"van Dijk","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0660","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/070674370505000415","article-title":"Aripiprazole reduces alcohol use","volume":"50","author":"Warsi","year":"2005","journal-title":"Canadian Journal of Psychiatry"},{"issue":"7","key":"10.1016\/bs.apha.2017.09.009_bb0665","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.1016\/bs.apha.2017.09.009_bb0670","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/cn400121z","article-title":"Classics in chemical neuroscience: Clozapine","volume":"4","author":"Wenthur","year":"2013","journal-title":"ACS Chemical Neuroscience"},{"issue":"4","key":"10.1016\/bs.apha.2017.09.009_bb0675","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S2215-0366(15)00575-1","article-title":"Predictors of treatment resistance in patients with schizophrenia: A population-based cohort study","volume":"3","author":"Wimberley","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/bs.apha.2017.09.009_bb0680","first-page":"S262","article-title":"Altered cerebral processing of reward uncertainty in patients with schizophrenia while medication-free and on atypical neuroleptics","volume":"30","author":"Wint","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2017.09.009_bb0685","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e31828b2575","article-title":"Do atypical antipsychotics really enhance smoking reduction more than typical ones?: The effects of antipsychotics on smoking reduction in patients with schizophrenia","volume":"33","author":"Wu","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0690","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s002139900339","article-title":"Inhibitory effects of clozapine and other antipsychotic drugs on noradrenaline transporter in cultured bovine adrenal medullary cells","volume":"149","author":"Yoshimura","year":"2000","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2017.09.009_bb0695","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00004714-200002000-00016","article-title":"Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey","volume":"20","author":"Zimmet","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2017.09.009_bb0700","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.schres.2013.05.002","article-title":"Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia","volume":"148","author":"Zugman","year":"2013","journal-title":"Schizophrenia Research"}],"container-title":["Advances in Pharmacology","Apprentices to Genius: A tribute to Solomon H. Snyder"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358917300881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358917300881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T20:10:50Z","timestamp":1751227850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358917300881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128140871"],"references-count":140,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2017.09.009","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}